Valeo Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$201K Buy
+3,689
New +$194K ﹤0.01% 765
2025
Q3
Sell
-6,245
Closed -$304K 845
2025
Q2
$304K Buy
+6,245
New +$242K 0.01% 577
2025
Q1
Sell
-6,358
Closed -$250K 707
2024
Q4
$250K Sell
6,358
-1,175
-16% -$55.5K 0.01% 598
2024
Q3
$354K Sell
7,533
-150
-2% -$7.61K 0.01% 495
2024
Q2
$415K Sell
7,683
-1,696
-18% -$98.1K 0.01% 439
2024
Q1
$522K Sell
9,379
-497
-5% -$35.6K 0.02% 367
2023
Q4
$618K Sell
9,876
-550
-5% -$30.4K 0.03% 307
2023
Q3
$473K Buy
10,426
+3,430
+49% +$177K 0.02% 347
2023
Q2
$393K Sell
6,996
-2,362
-25% -$134K 0.02% 363
2023
Q1
$423K Buy
9,358
+2,313
+33% +$112K 0.02% 365
2022
Q4
$286K Buy
7,045
+298
+4% +$15.8K 0.02% 398
2022
Q3
$441K Sell
6,747
-2,800
-29% -$203K 0.03% 280
2022
Q2
$580K Buy
9,547
+638
+7% +$37.5K 0.04% 234
2022
Q1
$559K Buy
8,909
+1,451
+19% +$91.1K 0.03% 305
2021
Q4
$565K Buy
7,458
+1,420
+24% +$124K 0.03% 280
2021
Q3
$676K Buy
6,038
+382
+7% +$48K 0.04% 239
2021
Q2
$916K Sell
5,656
-5
-0.1% -$608 0.06% 176
2021
Q1
$690K Buy
5,661
+1,924
+51% +$291K 0.03% 226
2020
Q4
$572K Sell
3,737
-165
-4% -$19.5K 0.03% 231
2020
Q3
$326K Buy
3,902
+33
+0.9% +$2.93K 0.03% 244
2020
Q2
$284K Buy
3,869
+3,066
+382% +$179K 0.03% 262
2020
Q1
$37K Buy
803
+53
+7% +$2.74K ﹤0.01% 694
2019
Q4
$46K Buy
750
+110
+17% +$6.01K ﹤0.01% 681
2019
Q3
$26K Sell
640
-85
-12% -$4.06K ﹤0.01% 776
2019
Q2
$34K Hold
725
﹤0.01% 701
2019
Q1
$26K Buy
725
+302
+71% +$10.4K ﹤0.01% 703
2018
Q4
$12K Buy
423
+44
+12% +$1.53K ﹤0.01% 829
2018
Q3
$12K Buy
379
+294
+346% +$15.4K ﹤0.01% 909
2018
Q2
$4K Sell
85
-20
-19% -$1.14K ﹤0.01% 1185
2018
Q1
$5K Sell
105
-25
-19% -$1.03K ﹤0.01% 1121
2017
Q4
$3K Buy
130
+60
+86% +$1.14K ﹤0.01% 1105
2017
Q3
$1K Buy
+70
New +$1.27K ﹤0.01% 1083

Other funds holding CRSP